Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Immunogenicity of a third dose of BNT162b2 to ancestral SARS-CoV-2 & Omicron variant in adults who received two doses of inactivated vaccine

Nancy H. L. Leung, Samuel M. S. Cheng, Mario Martín-Sánchez, Niki Y. M. Au, Yvonne Y. Ng, Leo L. H. Luk, Karl C. K. Chan, John K. C. Li, Yonna W. Y. Leung, Leo C. H. Tsang, Sara Chaothai, Kelvin K. H. Kwan, Dennis K. M. Ip, Leo L. M. Poon, Gabriel M. Leung, J. S. Malik Peiris, View ORCID ProfileBenjamin J. Cowling
doi: https://doi.org/10.1101/2022.01.20.22269586
Nancy H. L. Leung
1WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong; Hong Kong Special Administrative Region, China
2Laboratory of Data Discovery for Health; Hong Kong Science and Technology Park, Hong Kong Special Administrative Region, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: bcowling@hku.hk leungnan@hku.hk
Samuel M. S. Cheng
1WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong; Hong Kong Special Administrative Region, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mario Martín-Sánchez
1WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong; Hong Kong Special Administrative Region, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Niki Y. M. Au
1WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong; Hong Kong Special Administrative Region, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yvonne Y. Ng
1WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong; Hong Kong Special Administrative Region, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leo L. H. Luk
1WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong; Hong Kong Special Administrative Region, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karl C. K. Chan
1WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong; Hong Kong Special Administrative Region, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John K. C. Li
1WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong; Hong Kong Special Administrative Region, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yonna W. Y. Leung
1WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong; Hong Kong Special Administrative Region, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leo C. H. Tsang
1WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong; Hong Kong Special Administrative Region, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sara Chaothai
1WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong; Hong Kong Special Administrative Region, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kelvin K. H. Kwan
1WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong; Hong Kong Special Administrative Region, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dennis K. M. Ip
1WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong; Hong Kong Special Administrative Region, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leo L. M. Poon
1WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong; Hong Kong Special Administrative Region, China
3HKU-Pasteur Research Pole, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong; Hong Kong Special Administrative Region, China
4Centre for Immunology and Infection; Hong Kong Science and Technology Park, Hong Kong Special Administrative Region, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gabriel M. Leung
1WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong; Hong Kong Special Administrative Region, China
2Laboratory of Data Discovery for Health; Hong Kong Science and Technology Park, Hong Kong Special Administrative Region, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. S. Malik Peiris
1WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong; Hong Kong Special Administrative Region, China
3HKU-Pasteur Research Pole, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong; Hong Kong Special Administrative Region, China
4Centre for Immunology and Infection; Hong Kong Science and Technology Park, Hong Kong Special Administrative Region, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Benjamin J. Cowling
1WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong; Hong Kong Special Administrative Region, China
2Laboratory of Data Discovery for Health; Hong Kong Science and Technology Park, Hong Kong Special Administrative Region, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Benjamin J. Cowling
  • For correspondence: bcowling@hku.hk leungnan@hku.hk
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background Limited data exist on antibody responses to mixed vaccination strategies involving inactivated COVID-19 vaccines, particularly in the context of emerging variants.

Methods We conducted an open label trial of a third vaccine dose of an mRNA vaccine (BNT162b2, Fosun Pharma/BioNTech) in adults aged ≥30 years who had previously received two doses of inactivated COVID-19 vaccine. We collected blood samples before administering the third dose and 28 days later, and tested for antibodies to the ancestral virus using a binding assay (ELISA), a surrogate virus neutralization test (sVNT) and a live virus plaque reduction neutralization test (PRNT). We also tested for antibodies against the Omicron variant using live-virus PRNT.

Results In 315 participants, a third dose of BNT162b2 substantially increased antibody titers on each assay. Mean ELISA levels increased from an optical density (OD) of 0.3 to 2.2 (p<0. 001), and mean sVNT levels increased from an inhibition of 17% to 96% (p<0.001). In a random subset of 20 participants, the geometric mean PRNT50 titers rose very substantially by at least 24 fold from Day 0 to Day 28 against the ancestral virus (p<0.001) and rose by at least 11 fold against the Omicron variant (p<0.001). In daily monitoring, post-vaccination reactions subsided within 7 days for over 99% of participants.

Conclusions A third dose of COVID-19 vaccination with an mRNA vaccine substantially improved antibody levels against the ancestral virus and the Omicron variant with well-tolerated safety profile, in adults who had received two doses of inactivated vaccine 6 months earlier.

Summary In this open label trial of Chinese adults aged ≥30 years who received two doses of inactivated COVID-19 vaccine 6 months earlier, third-dose mRNA vaccine substantially improved antibody levels against the ancestral virus and Omicron variant with well-tolerated safety profile.

Competing Interest Statement

BJC consults for AstraZeneca, Fosun Pharma, GlaxoSmithKline, Moderna, Pfizer, Roche and Sanofi Pasteur. The authors report no other potential conflicts of interest.

Clinical Trial

NCT05057182

Funding Statement

This project was supported by the Theme-based Research Scheme T11-712/19-N of the Research Grants Council of the Hong Kong Special Administrative Region, China (BJC). BJC is supported by a RGC Senior Research Fellow Scheme grant (HKU SRFS2021-7S03) from the Research Grants Council of the Hong Kong Special Administrative Region, China. The funding bodies had no role in the design of the study, the collection, analysis, and interpretation of data, or writing of the manuscript.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study protocol was approved by the Institutional Review Board of the University of Hong Kong/ Hospital Authority Hong Kong West Cluster

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Minor updates to statistical analysis. Added a new Table 2 with numerical summary of the mean/median antibody levels (complementing Figure 1). Minor updates to text throughout, addressing comments and suggestions from peer reviewers.

Data Availability

Anonymized raw data and R syntax to reproduce all the analyses, figures and tables in the published article will be made available after publication.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted March 31, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Immunogenicity of a third dose of BNT162b2 to ancestral SARS-CoV-2 & Omicron variant in adults who received two doses of inactivated vaccine
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Immunogenicity of a third dose of BNT162b2 to ancestral SARS-CoV-2 & Omicron variant in adults who received two doses of inactivated vaccine
Nancy H. L. Leung, Samuel M. S. Cheng, Mario Martín-Sánchez, Niki Y. M. Au, Yvonne Y. Ng, Leo L. H. Luk, Karl C. K. Chan, John K. C. Li, Yonna W. Y. Leung, Leo C. H. Tsang, Sara Chaothai, Kelvin K. H. Kwan, Dennis K. M. Ip, Leo L. M. Poon, Gabriel M. Leung, J. S. Malik Peiris, Benjamin J. Cowling
medRxiv 2022.01.20.22269586; doi: https://doi.org/10.1101/2022.01.20.22269586
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Immunogenicity of a third dose of BNT162b2 to ancestral SARS-CoV-2 & Omicron variant in adults who received two doses of inactivated vaccine
Nancy H. L. Leung, Samuel M. S. Cheng, Mario Martín-Sánchez, Niki Y. M. Au, Yvonne Y. Ng, Leo L. H. Luk, Karl C. K. Chan, John K. C. Li, Yonna W. Y. Leung, Leo C. H. Tsang, Sara Chaothai, Kelvin K. H. Kwan, Dennis K. M. Ip, Leo L. M. Poon, Gabriel M. Leung, J. S. Malik Peiris, Benjamin J. Cowling
medRxiv 2022.01.20.22269586; doi: https://doi.org/10.1101/2022.01.20.22269586

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (174)
  • Allergy and Immunology (421)
  • Anesthesia (97)
  • Cardiovascular Medicine (901)
  • Dentistry and Oral Medicine (170)
  • Dermatology (102)
  • Emergency Medicine (257)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (407)
  • Epidemiology (8790)
  • Forensic Medicine (4)
  • Gastroenterology (405)
  • Genetic and Genomic Medicine (1864)
  • Geriatric Medicine (179)
  • Health Economics (388)
  • Health Informatics (1292)
  • Health Policy (644)
  • Health Systems and Quality Improvement (492)
  • Hematology (207)
  • HIV/AIDS (395)
  • Infectious Diseases (except HIV/AIDS) (10567)
  • Intensive Care and Critical Care Medicine (564)
  • Medical Education (193)
  • Medical Ethics (52)
  • Nephrology (218)
  • Neurology (1756)
  • Nursing (103)
  • Nutrition (266)
  • Obstetrics and Gynecology (343)
  • Occupational and Environmental Health (461)
  • Oncology (965)
  • Ophthalmology (283)
  • Orthopedics (107)
  • Otolaryngology (177)
  • Pain Medicine (118)
  • Palliative Medicine (43)
  • Pathology (264)
  • Pediatrics (557)
  • Pharmacology and Therapeutics (266)
  • Primary Care Research (219)
  • Psychiatry and Clinical Psychology (1845)
  • Public and Global Health (3986)
  • Radiology and Imaging (655)
  • Rehabilitation Medicine and Physical Therapy (344)
  • Respiratory Medicine (535)
  • Rheumatology (215)
  • Sexual and Reproductive Health (178)
  • Sports Medicine (166)
  • Surgery (197)
  • Toxicology (37)
  • Transplantation (106)
  • Urology (80)